Concepedia

Haiqing Ni

HN

8

Publications

448

Citations

8

H-Index

2019

Active since

Affiliations

Adimab (United States)(Current)

Zhejiang University

Haiqing Ni is an author at Adimab (United States) specializing in immunology, immunotherapy, and medicine.

Top concepts

Publications per year

2019–2024

8

Publications

8

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

Jie Wang, Keke Fei, Jing Hua et al. · mAbs · 2019 · 148 citations · Full text

, , +24

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

Yan Wang, Haiqing Ni, Shuaixiang Zhou et al. · Cancer Immunology Immunotherapy · 2020 · 103 citations · Full text

, , +10

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Haiping Jiang, Haiqing Ni, Pan Zhang et al. · OncoImmunology · 2021 · 98 citations · Full text

Development and characterization of a novel anti-OX40 antibody for potent immune activation

Zhihui Kuang, Jing Hua, Zhihai Wu et al. · Cancer Immunology Immunotherapy · 2020 · 30 citations · Full text

, , +10

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody

Haiqing Ni, Lei Cao, Zhihai Wu et al. · Cancer Immunology Immunotherapy · 2021 · 28 citations · Full text

, , +11

Rows per page

1–5 of 8